Letters
Life without COX 2 inhibitors: Risks and benefits are determined by dose and potency
BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7555.1451-b (Published 15 June 2006) Cite this as: BMJ 2006;332:1451
- Enrique J Sánchez-Delgado, professor (esanchez@metropolitano.com.ni)
- Hospital Metropolitano Vivian Pellas, Managua, Nicaragua
EDITOR—The paper by Kearney et al on the risk of atherothrombosis with cyclo-oxygenase-2 (COX 2) inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs) supports the data of Hippisley-Cox et al, who revised the gastrointestinal risks of these drugs.1 2
A clear picture is forming, that the risks and benefits are determined by doses and potencies more than by their selectivity to the cyclo-oxygenases, with the exception of low dose aspirin, which permanently inhibits platelet …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.